New diabetes meds may shield eyes from vision loss
NCT ID NCT07351786
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether newer diabetes drugs (SGLT2 inhibitors and DPP-4 inhibitors) can delay or prevent diabetic retinopathy, an eye disease that can lead to vision loss. Researchers will compare these newer drugs to older treatments in 70 people with type 2 diabetes. The goal is to see if early use of these drugs can reduce the burden of eye disease and improve quality of life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES (DM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Alexandria University Main Hospitals - Diabetes clinics/ Ophthalmology clinics
RECRUITINGAlexandria, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could your bone health decide if a dental implant lasts?
- Could a blood flow 'Tourniquet' workout repair diabetic nerve damage?
- Could a common diabetes drug weaken your bones?
- Can a spice and a mindset shift ease diabetic nerve pain?
- Ancient wisdom meets modern care: could chinese medicine boost diabetes Self-Management?
- Could a peptide injection help rebuild Insulin-Making cells?